BMRN Research and Charts

BMRN - Biomarin Pharmaceutical Inc (Healthcare: Biotechnology)

Projected Earnings Date: 2025-07-31 (Delayed quote data 2025-05-08)

Last 59.82	Change ⇑ +0.50 (+0.84%)	Volume 1,465,951
	Open 58.86	High 61.26	Low 58.74

8EMA (Daily) 60.89	40EMA (Daily) 63.31	50EMA (Daily) 63.84	STO (Daily) 34.673	MACD Hist (Daily) -0.110
8EMA (Weekly) 62.519	40EMA (Weekly) 69.06	50EMA (Weekly) 70.86	STO (Weekly) 35.462	MACD Hist (Weekly) -0.643


Company Profile
BioMarin's focus is on rare-disease therapies. Genzyme (now part of Sanofi) markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU (in addition to long-standing U.S. rights, BioMarin has reacquired international rights for Kuvan and Palynziq from Merck KGaA). BioMarin has a hemophilia A gene therapy and a treatment for achondroplasia in late-stage clinical trials.

Disclaimer: All information provided is for informational purposes only and not intended for trading purposes or advice. The quotes and charts are not real time and have delays of at least 20 minutes. Data accuracy cannot be guaranteed as errors will occur. Please do not rely on the above information to make your stock/option trades. Neither OptionChance.com nor any of independent data providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.